Celebrating the discovery of mutated CALR
MPN Research Foundation is proud to celebrate the 10-year anniversary of the identification of CALR as a common driver of MPNs. We funded early work that discovered this MPN driver mutation. Learn more >
MPNRF by the numbers
Total donated dollars
invested in research
$ 0 M
Researchers supported
0
Countries with
supported research
0
Projects funded
0

What is
essential
thrombocythemia
(ET)
?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is
polycythemia vera
(PV)
?

Polycythemia vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

What is
myelofibrosis
(MF)
?

Myelofibrosis (MF)

MF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF
Patients, clinicians, researchers, and the biotech and pharma industries all have critical roles to play in advancing MPN research and are all important members of the MPNRF community.
Connect with us to be part of our coordinated effort to find new treatments — and eventually cures — for MPNs.

Patients
and Caregivers

Every patient experience is unique and provides new clues for researchers and clinicians.

Researchers
and
Clinicians

In our 24-year history, MPNRF has contributed to some of the most influential MPN research discoveries.

Industry
and
Biopharma

Engage with us to ensure that new therapies have the maximum impact on patient outcomes and quality of life.

Download our Voice of the Patient report

Ready to do more?

Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

Stay connected

Invest in MPN research

Your investment supports doctors and researchers around the world who are dedicated to finding cures for MPNs.

 INVEST NOW

Join the community
Be the first to know about the latest news and advancements for ET, PV, and MF. Sign up to receive our newsletters and alerts.

Recent news

  • Remembering Zhenya Senyak

    MPN NEWS | September 3, 2024

    It is with a heavy heart that we announce the passing of Zhenya Senyak, who has died surrounded by his loving family in Asheville NC, after a long journey with illness. Those who have been in the MPN community for some time will recognize Zhenya’s passing as a watershed event.  His dedication, resolve, and tireless… Read More »Remembering Zhenya Senyak

    READ MORE

    New Study Reveals On-Off Switch for Platelet Production  

    MPN NEWS | August 27, 2024

    “This new work from Gaertner et al. is significant and potentially field-changing,” says Anandi Krishnan PhD from Rutgers University, commenting on the new Nature journal study. “This is especially relevant in the context of managing blood disorders such as MPNs.”   The study does not mention ‘cancer’ or ‘myeloproliferation,’ yet its findings may be crucial… Read More »New Study Reveals On-Off Switch for Platelet Production  

    READ MORE

    Marina Kremyanskaya, MD, PhD Research Profile

    MPN NEWS | August 23, 2024

    Profile: Marina Kremyanskaya MD, PhD Icahn School of Medicine, New York, NY, USA  From Bench to Bedside: Dr. Marina Kremyanskaya’s Mission to Revolutionize MPN Treatment Downplaying a cure “It is an experimental treatment. There is no doubt about it,” Marina Kremyanskaya MD, PhD, states plainly about a new anti-cancer vaccine for patients with myeloproliferative neoplasms… Read More »Marina Kremyanskaya, MD, PhD Research Profile

    READ MORE